Opinion|Videos|July 29, 2024
Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Treatment options post progression on CDK4/6i + ET
- What is your overall perception on the class of oral SERDs? How will they continue to impact the treatment landscape?
- What are your perceptions on efficacy and safety data? What has your experience been in practice with:
- Elacestrant
ASCO 2024 #1071 : Real-world (RW) elacestrant use patterns and therapeutic outcomes.ASCO 2024 #1064 : Elacestrant plus abemaciclib Preliminary data from ELECTRAASCO 2024 #1069 : Elacestrant in various combinations: Preliminary data from ELEVATEBardia Cancer Res 2023 : GS3-01 EMERALD phase 3 trial of elacestrant vs endocrine therapy: Updated results by duration of prior CDK4/6i in metastatic setting
- Elacestrant
Advertisement
Related to this article
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.
Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5